Optos Stock Rating Upgraded by N+1 Singer (OPTS)
Optos (LON:OPTS) was upgraded by analysts at N+1 Singer to a “buy” rating in a research report issued to clients and investors on Monday, Stock Ratings Network.com reports. The firm currently has a GBX 260 ($4.26) target price on the stock, up from their previous target price of GBX 154 ($2.53). N+1 Singer’s price target suggests a potential upside of 30.49% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Numis Securities Ltd reiterated a “buy” rating on shares of Optos in a research note to investors on Friday, December 13th. They now have a GBX 300 ($4.92) price target on the stock, up previously from GBX 180 ($2.95). Separately, analysts at Canaccord Genuity cut their price target on shares of Optos from GBX 248 ($4.07) to GBX 231 ($3.79) in a research note to investors on Monday, November 25th. They now have a “buy” rating on the stock. Finally, analysts at Investec reiterated a “reduce” rating on shares of Optos in a research note to investors on Thursday, November 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. Optos presently has an average rating of “Buy” and an average target price of GBX 228.50 ($3.75).
Shares of Optos (LON:OPTS) opened at 199.00 on Monday. Optos has a 52-week low of GBX 106.75 and a 52-week high of GBX 221.00. The stock has a 50-day moving average of GBX 181.3 and a 200-day moving average of GBX 157.0. The company’s market cap is £143.7 million.
Optos Plc is a retinal imaging company. The Company’s medical devices produce ultra-widefield, high resolution digital images of approximately 82% of the retina in a single capture.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.